###### Strengths and limitations of this study

-   To our knowledge, this is the first study that investigates the impact of fluoroquinolone therapeutic drug monitoring (TDM) on sputum smear and culture conversion rates in prospective patients with multidrug-resistant tuberculosis (MDR-TB) versus historical controls without TDM.

-   The feasibility for centralised TDM will be evaluated due to the participation of multiple healthcare centres located in differently-resourced countries from multiple regions in the world.

-   The use of limited sampling strategies will reduce the burden of TDM for patients and healthcare providers while still providing a reliable estimation of drug exposure.

-   A limitation is that this study focuses on TDM for moxifloxacin and levofloxacin only, being core drugs in MDR-TB treatment, without assessing other (core) anti-TB drugs.

Introduction {#s1}
============

Tuberculosis (TB) is one of the major infectious diseases worldwide with an estimated number of 10 million new cases in 2017.[@R1] In addition, multidrug-resistant TB (MDR-TB) remains a persistent problem with an estimated 458 000 new patients in 2017.[@R1] MDR-TB is treated from 9 to 20 months with a multidrug regimen.[@R2] The grouping of second-line anti-TB drugs was revised in 2018 by the WHO.[@R3] The fluoroquinolones, specifically moxifloxacin and levofloxacin, are now considered drugs of first choice (group A drugs), together with bedaquiline and linezolid, in the treatment of MDR-TB.[@R2] The administration of group A medicines to patients with MDR-TB has been associated with increased treatment success and reduced mortality rates in comparison with other second-line anti-TB drugs.[@R4] However, the estimated prevalence of fluoroquinolone resistance among MDR-TB cases is on the rise from 14.5% in 2011 to 22% in 2017.[@R5] Mismanagement of MDR-TB treatment, especially the shorter regimen, could amplify the risk of drug resistance even further.[@R7] Importantly, antibiotic resistance can be acquired due to non-compliance but also insufficient drug exposures (eg, interindividual pharmacokinetic variability in patients treated with fluoroquinolones).[@R8] Therapeutic drug monitoring (TDM) can help to prevent acquired resistance by individualising doses based on blood drug concentrations relative to the bacterial susceptibility, ideally measured as the minimal inhibitory concentration (MIC).[@R7]

Several studies described the role played by low drug concentrations on treatment outcomes.[@R13] In the light of this evidence, it can be hypothesised that TDM, which aims for adequate dosing and exposure, could improve treatment outcomes. Yet, the added value of TDM in MDR-TB treatment outcomes has not been directly studied.[@R16] One retrospective study reported the effect of TDM on the treatment results of patients with drug-susceptible TB, either with and without diabetes.[@R18] In the group without diabetes, TDM had a significant beneficial effect with 73% sputum culture conversion at 2 months among patients receiving TDM versus 60% in the control group. The positive effect of TDM was even larger in patients with diabetes and TB. The isoniazid or rifampicin dose was adjusted in 12 out of 17 (71%) of the patients with diabetes based on peak concentration (C~max~) targets. However, this data is not available for the group without diabetes. To the best of our knowledge, such controlled studies have not yet been performed in people with MDR-TB.

The pharmacokinetic-pharmacodynamic parameter of fluoroquinolones is both time-dependent and concentration-dependent and therefore uses the ratio of area under the concentration--time curve (AUC) to MIC (AUC~0--24~/MIC). The target value is AUC~0--24~/MIC \>146 for levofloxacin and free or unbound *f*AUC~0--24~/MIC \>53 for moxifloxacin which corresponds to a total (bound and unbound) AUC~0--24~/MIC \>106 assuming a constant protein binding of 50%.[@R19] However, multiple concentration measurements widely distributed over the dosing interval are required to compute the AUC from 0 to 24 hours (AUC~0--24~). Limited sampling strategies (LSSs) could be adopted to reduce the burden of frequent sampling for both patient and personnel while providing a reliable estimation of AUC~0--24~ using only two blood samples.[@R21]

Unfortunately, TDM is not always easily accessible in high-TB-burden areas because of practical and financial reasons. Therefore, centralised TDM could be a valuable service.[@R23] Large laboratories are generally well organised, have highly trained personnel with the adequate performance of analytical methods leading to reliable sample analysis results.[@R24] In addition, centralising the TDM procedures will engender more consistent practice from healthcare practitioners familiar with TDM and the provision of dosing advice for anti-TB drugs.

The aim of the present study is: first, to investigate the feasibility of centralised TDM of moxifloxacin and levofloxacin in the treatment of MDR-TB recruited in TB reference centres located in different continents. Second, the impact of TDM on treatment results will be assessed by comparing 2 month sputum smear and culture conversion rates among patients who received TDM compared with matched historical controls without TDM.

Methods and analysis {#s2}
====================

Study design {#s2-1}
------------

This observational, prospective, multicentre study aims to evaluate the feasibility of centralised TDM of moxifloxacin and levofloxacin as well as the impact of TDM on 2 month sputum smear and culture conversion rates of patients with MDR-TB. Study design and procedures are displayed in [figure 1](#F1){ref-type="fig"}. The study was registered at clinicaltrials.gov, recruitment started on 10 February 2018, and is expected to be completed in December 2020.

![Workflow of study procedures in local hospitals and central laboratory facility. MDR-TB, multidrug-resistant tuberculosis; TDM, therapeutic drug monitoring.](bmjopen-2019-035350f01){#F1}

Study location {#s2-2}
--------------

University Medical Center Groningen (UMCG) in Groningen, The Netherlands, is the coordinating centre and serves as the central laboratory facility for this study. The hospitals that are involved in patient recruitment are displayed in [table 1](#T1){ref-type="table"}.

###### 

List of participating hospitals and their location

  Hospital                                                                      Location
  ----------------------------------------------------------------------------- ----------------------------
  University Medical Center Groningen (Central Lab Facility)                    Groningen, The Netherlands
  Tuberculosis Clinic "Beatrixoord", UMCG                                       Haren, The Netherlands
  Princess Alexandra Hospital                                                   Brisbane, Australia
  Karolinska University Hospital                                                Stockholm, Sweden
  Instituto Nacional de Enfermedades Respiratorias                              Mexico City, Mexico
  Athens Chest Hospital "Sotiria"                                               Athens, Greece
  Kibong'oto Infectious Diseases Hospital                                       Kilimanjaro, Tanzania
  Republican Scientific and Practical Centre for Pulmonology and Tuberculosis   Minsk, Belarus
  Barts Health NHS Trust                                                        London, UK
  St. Orsola-Malpighi Hospital, University of Bologna                           Bologna, Italy
  Riga East University Hospital TB and Lung Disease Clinic                      Riga, Latvia

NHS, National Health Service; TB, tuberculosis; UMCG, University Medical Center Groningen.

Study population {#s2-3}
----------------

Patients aged 18 years and older are eligible for inclusion if they are diagnosed with pulmonary MDR-TB, have positive sputum smear and culture samples at the time of inclusion, are treated with either oral moxifloxacin or levofloxacin, and provide written informed consent. Pregnant or breastfeeding women will be excluded. The decision whether a patient is treated with either moxifloxacin or levofloxacin is made by the clinician at the start of TB treatment based on local guidelines. Patients will not be actively assigned to use moxifloxacin or levofloxacin since this is an observational study.

A total number of 120 patients (60 with moxifloxacin and 60 with levofloxacin) will be prospectively included and compared with 240 matched historical controls (120 with moxifloxacin and 120 with levofloxacin).

The following data will be collected in both groups: sex, age, body weight, height, country of birth, country of residence, comorbidities, QTc interval, laboratory values (kidney and liver function, electrolytes), history of previous TB treatment, bacterial susceptibility (including MIC if available), TB presentation (cavitary or non-cavitary), current MDR-TB regimen (including drug dosages), sputum smear and culture data, treatment outcome (if known) and details on fluoroquinolone use (duration, possible drug interactions or adverse events).

Historical control patients will be matched on age, sex, *Mycobacterium tuberculosis* resistance pattern of the isolate (only regimen core drugs), comorbidities (HIV, diabetes and immunosuppression), presence or absence of cavitary TB on chest radiography and dosing of the fluoroquinolone (mg/kg body weight, ±10%) to prospectively enroled patients in a 2:1 ratio.

Interventions {#s2-4}
-------------

The objective of the feasibility of centralised TDM will be assessed by evaluating the process, by which a locally collected sample will be analysed in a central laboratory and subsequent dosing advice will be returned to the local physician. In brief, after at least 7 days of treatment (steady state), two blood samples will be collected for TDM of moxifloxacin or levofloxacin according to a previously developed LSS.[@R21] The first sample will be collected just before drug intake (t=0) and the other at 5 hours after drug intake (t=5). Samples will be transported to the central laboratory for drug analysis and will be accompanied by a form including key patient characteristics for personalised dosing advice (ie, sex, age, weight, height, serum creatinine, QTc interval, MIC, TB presentation, start of treatment, other anti-TB drugs and comorbidities). AUC~0--24~ will be calculated using a population pharmacokinetic model[@R21] and Bayesian dose optimisation in MWPharm++ (V.1.7.3; Mediware, Groningen, The Netherlands).

Dosing is optimised based on AUC~0--24~/MIC or AUC~0--24~ (in case MIC is unknown), taking into consideration comorbidities (HIV, diabetes and immunosuppression), the persistence of TB symptoms and response to treatment so far. The Bayesian dosing software uses sex, age, height, weight and renal function in addition to drug dose and measured drug concentrations to forecast the drug exposure after a dose change. For patients who are at risk for treatment failure due to the previously mentioned reasons, a higher drug exposure is recommended. This is especially relevant in the case of an unknown individual MIC since the actual MIC might be near the breakpoint, to prevent treatment failure and acquired resistance. The target AUC~0--24~/MIC and AUC~0--24~ are shown in [table 1](#T1){ref-type="table"}. If a dose change is necessary, TDM is to be repeated after at least 7 days after the initiation of the new dose (steady state). Dose increases of moxifloxacin will not be advised in the case of a prolonged QTc interval (\>450 ms for men and \>470 ms for women) because of safety reasons. As levofloxacin may be less cardiotoxic than moxifloxacin, levofloxacin dose increases are permitted in the case of prolonged QTc interval, but only with adequate electrocardiogram monitoring. Patients with prolonged QTc interval will not be excluded from the study since TDM can still be helpful to verify drug exposure. A closely monitored follow-up including MIC determination can be advised in the case of AUC~0--24~ of 25-- 40 mg\*h/L in combination with QTc interval prolongation. In the case of very low moxifloxacin exposure (AUC~0--24~\<20 mg\*h/L) in combination with a prolonged QTc interval, the physician will be advised to reconsider the anti-TB regimen as moxifloxacin may be less active than expected.

Laboratory methods {#s2-5}
------------------

### Drug analysis {#s2-5-1}

Measurement of moxifloxacin and levofloxacin plasma/serum concentrations will take place at the laboratory of the Department of Clinical Pharmacy and Pharmacology in the UMCG, The Netherlands, and using validated liquid chromatography-mass spectrometry methods. The method for levofloxacin has an accuracy of 0.1%--12.7%, within-run precision of 1.4%--2.4% and between-run precision of 3.6%--4.1%. The calibration curve is linear over a range of 0.10--5.00 mg/L.[@R25] This range was successfully expanded to 0.20--50.0 mg/L in a recent update of the method (data on file). Accuracy of the moxifloxacin method is 2.7%--7.1%, within-run precision 1.4%--1.6% and between-run precision 1.0%--1.6%. The calibration curve is linear over a range of 0.05--5.00 mg/L.[@R26] For both fluoroquinolones, only the total concentration (bound and unbound) will be measured. Therefore, the target AUC~0--24~/MIC values of \>150[@R19] and \>100[@R20] will be used for levofloxacin and moxifloxacin, respectively ([table 2](#T2){ref-type="table"}).

###### 

Target AUC~0--24~/MIC and AUC~0--24~ for TDM of moxifloxacin and levofloxacin in patients with MDR-TB

  Fluoroquinolone                   Pulmonary MDR-TB   Target AUC~0--24~/MIC\*   Target AUC~0--24~ (mg\*h/L)            
  --------------------------------- ------------------ ------------------------- ----------------------------- -------- -------
  Moxifloxacin                      Standard disease   \>100                     \>50                          \>25     \>40
  Severe disease or comorbidities   \>100              \>50                      \>25                          \>60†    
  Levofloxacin                      Standard disease   \>150                     \>150‡                        \>75     \>150
  Severe disease or comorbidities   \>150              \>150‡                    \>75                          \>200†   

Standard disease is defined as non-cavitary and regular disease on the radiograph. Severe disease is defined as cavitary or extensive disease on the radiograph.

\*MIC varies depending on growth media; mycobacteria growth indicator tubes (MGIT), Middlebrook 7H10/7H11, and Lowenstein-Jensen (LJ) agar.

†Target AUC~0--24~/MIC at site of cavity; therefore, higher AUC~0--24~ is required.

‡Levofloxacin critical concentration of 7H11 was extrapolated to 7H10.

AUC, area under the concentration--time curve; LJ, Lowenstein-Jensen; MDR-TB, multidrug-resistant tuberculosis; MGIT, mycobacteria growth indicator tubes; MIC, minimal inhibitory concentration; TDM, therapeutic drug monitoring.

Plasma and serum samples containing levofloxacin are stable for at least 10 days at 50°C and can, therefore, be transported to the central facility in ambient temperature, without the need of transport on dry ice.[@R27] The thermal stability of moxifloxacin was also tested according to the method of Ghimire *et al* and showed that moxifloxacin serum and plasma samples are stable for at least 10 days at 50°C as well (data on file).

### Microbiology {#s2-5-2}

The assessment of sputum smear and culture status after 2 months of MDR-TB treatment will be performed according to the local procedures, but at least once a month until documented culture conversion. MIC determination is preferred but not mandatory for TDM and will be performed according to local procedures as well. To account for the differences in culture media used in drug susceptibility testing, correction factors based on the critical concentrations in the WHO document 'Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis' will be applied.[@R28] The target AUC~0--24~/MIC values for each medium are shown in [table 2](#T2){ref-type="table"}. Furthermore, second-line molecular drug susceptibility tests will be considered in case MIC data are not available.

Data analysis plan {#s2-6}
------------------

The primary outcome to assess the feasibility of centralised TDM will be the turn-around time, which is defined by the time between blood sampling and the peripheral centres receiving the TDM results including the dosing advice. The procedure is considered feasible if \>80% of the collected samples will be reported back to the physician within 7 days and 100% within 2 weeks. Additionally, the feasibility will be evaluated using secondary outcomes of sample quality after shipping and completeness of required information on the sample form.

Furthermore, we will evaluate the role of TDM on MDR-TB treatment by comparing the percentages of patients with sputum smear and culture conversion at 2 months in the enrolled groups. In addition, we will evaluate the number of patients with low fluoroquinolone exposure requiring dose changes after TDM to estimate the potential gains.

Sample size calculation {#s2-7}
-----------------------

As the primary endpoint was of descriptive nature and no data were available to perform a well-informed sample size calculation, it was decided to power the study on the clinical impact of TDM. The primary assumption was based on the detection of a proportional difference in sputum smear and culture positivity at 2 months of treatment in patients with MDR-TB undergoing TDM (35%)[@R29] and control patients (60%).[@R30] Given an alpha error of 0.05 and statistical power of 80%, we calculated a sample size of 60 per single group (ie, 60 prospective and 120 historical control patients for moxifloxacin and equally for levofloxacin).

Patient and public involvement {#s3}
==============================

There has been no patient or public involvement in the design of this study.

Ethics and dissemination {#s4}
========================

This study will be performed according to the Declaration of Helsinki and Good Clinical Practice.[@R31] In each recruiting centre, ethical clearance has been granted according to local regulations and patient recruitment has begun at most sites ([online supplementary file 1](#SP1){ref-type="supplementary-material"}). Written informed consent will be obtained from all patients undergoing TDM. The need of new informed consent for historical controls was waived because of the use of retrospective anonymous data collected for programmatic purposes or previously reported data from studies for which patients had provided informed consent.
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This study includes historical patients who did not receive TDM as controls instead of prospectively randomising patients to either receive or not receive TDM for ethical reasons. The evidence that TDM actually improves MDR-TB treatment outcomes has not been confirmed in randomised controlled trials, but multiple studies have described treatment failure and risk of antibiotic resistance due to subtherapeutic drug exposure of anti-TB drugs.[@R8] In combination with a large between-patient pharmacokinetic variability,[@R9] we hypothesise that TDM is able to improve treatment outcomes by ensuring adequate exposure in individual patients. Moreover, TDM for MDR-TB is recommended in guidelines when it is available.[@R2] We, therefore, considered it unethical to withhold TDM.

Study results will be published in a peer-reviewed journal and will be presented at an international conference.

Discussion {#s5}
==========

We present an observational prospective multicentre study which aims to: (a) evaluate the feasibility of centralised TDM in differently resourced settings of varying TB endemicity and geographic region and (b) evaluate the role of TDM of moxifloxacin or levofloxacin on sputum smear and culture conversion rates in patients with MDR-TB after 2 months of treatment.

Presently, TDM is offered as an adjunctive to patients with TB in only a few hospitals worldwide and is considered to be part of the excellent clinical care.[@R16] However, general interest in TDM and MDR-TB treatment optimisation has been increasing. A consensus statement on the diagnosis and treatment of MDR-TB in Europe states that TDM for second-line drugs should be used if available.[@R33] Moreover, the use of second-line anti-TB drugs was listed in the American Thoracic Society guidelines as an indication for TDM and TDM is also recommended in the European Union Standards for Tuberculosis Prevention and Care.[@R32] Yet, TDM is considered by some to be laborious, expensive and thus unpractical in countries with high TB incidence. Similar injurious arguments of economistic rationing of services were applied to second-line drugs for the treatment of MDR-TB in highly endemic settings and such rationing conversely led to amplification of the MDR-TB epidemic.[@R38] This study will focus on the feasibility of centralised TDM, which could stimulate performing TDM more often as it requires only one qualified laboratory with validated analytical methods and devices in a central location. Other options to facilitate TDM are the implementation of LSSs, urine samples, dried-blood spots and saliva-screening methods.[@R34] This study will additionally use LSSs to increase feasibility as well as to reduce the burden of TDM. The LSSs for moxifloxacin and levofloxacin used in this study (0 and 5-hour postdose samples) were designed to optimise AUC~0--24~,[@R21] whereas the frequently used sampling schedule at 2-hour and 6-hour postdose is more suitable to estimate C~max~ and identify delayed absorption.[@R42]

Although incorporating TDM in TB treatment has shown to give high treatment success rates in low endemic countries, such as The Netherlands,[@R29] this has not yet been evaluated in well-designed randomised controlled trials.[@R43] This study will provide a first-ever conclusion on the value of TDM of moxifloxacin and levofloxacin on sputum smear and culture conversion of patients with MDR-TB.

It can be considered a limitation that only TDM of fluoroquinolones is performed in this study. However, moxifloxacin and levofloxacin are currently among the core drugs in the MDR-treatment regimen together with linezolid and bedaquiline.[@R3] Based on TDM criteria,[@R44] we have selected moxifloxacin and levofloxacin because they show large interindividual pharmacokinetic variability, which emphasises the need for personalised dosing.[@R9] Moreover, fluoroquinolone resistance is on the rise and can develop during low drug exposure.[@R8] TDM of fluoroquinolones aims to find the individual patients who have low drug exposure and would benefit from dose adjustment. Therefore, it is expected that the TDM of fluoroquinolones will have the largest impact on MDR-TB treatment outcomes. We did not include TDM for linezolid and bedaquiline in this study because of unclear evidence for TDM of bedaquiline due to the novelty of the drug[@R45] and TDM of linezolid has focused more on preventing toxicity.[@R46]

Another limitation is that we are only evaluating interim outcomes such as sputum conversion rates at 2 months and will not assess outcomes at the end of treatment. However, this study is primarily designed to determine the feasibility of centralised TDM. In addition, this is the first study to evaluate the impact of fluoroquinolone TDM. We believe that reporting the results on sputum conversion rates is relevant as bacterial load and risk of acquired resistance are highest in the first months of therapy. Fast sputum culture conversion reduces the risk of transmission of *M. tuberculosis* strains which continues to sustain the MDR-TB epidemic.[@R49] With the results of this study, we aim to design a future study to extensively evaluate TDM of all drugs in the regimen including the final treatment outcomes. However, such study would require substantial funding.

We hope that this study will show that centralised TDM is feasible and that TDM can improve the quality of treatment in terms of faster sputum conversion rates compared with historical experience. If that might be the case, the major hesitations about TDM in TB treatment can be attenuated favouring the improvement of TB management using a personalised approach.[@R37]
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